Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
Tobias TägerLutz FrankensteinDan AtarStefan AgewallNorbert FreyMorten GrundtvigAndrew L ClarkJohn G F ClelandHanna FröhlichPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2021)
Our data point towards a class-effect of SGLT2i on mortality and renal outcomes. However, non-selective SGLT2i such as sotagliflozin may be superior to highly selective SGLT2i in terms of HF outcomes.